Lifeboat Foundation

Development of medical treatment against cancer is a major research topic worldwide — but cancer often manages to circumvent the solutions found. Scientists around Tanja Weil and David Ng at the Max Planck Institute for Polymer Research (MPI-P), have now taken a closer look at the cancer’s countermeasures and aim to stop them. By disrupting the cellular components that are responsible for converting oxygen into chemical energy, they have demonstrated initial success in eliminating cells derived from untreatable metastatic cancer.

Treatment of cancer is a long-term process because remnants of living cancer cells often evolve into aggressive forms and become untreatable. Hence, treatment plans often involve multiple drug combinations and/or radiation therapy in order to prevent cancer relapse. To combat the variety of cancer cell types, modern drugs have been developed to target specific biochemical processes that are unique within each cell type.

However, cancer cells are highly adaptive and able to develop mechanisms to avoid the effects of the treatment. “We want to prevent such adaptation by invading the main pillar of cellular life — how cells breathe – that means take up oxygen — and thus produce chemical energy for growth,” says David Ng, group leader at the MPI-P.

The laser that will be the most powerful in the United States is preparing to send its first pulses into an experimental target at the University of Michigan.

Called ZEUS, the Zetawatt-Equivalent Ultrashort pulse laser System, it will explore the physics of the quantum universe as well as outer space, and it is expected to contribute to new technologies in medicine, electronics and national security.

Continue reading “First light at the most powerful laser in the US” »

Optimizing Human-System Performance — Dr. Greg Lieberman, Ph.D., Neuroscientist / Lead, U.S. Army Combat Capabilities Development Command Army Research Laboratory, U.S. Army Futures Command

Dr. Greg Lieberman, Ph.D. (https://www.arl.army.mil/arl25/meet-arl.php?gregory_lieberman) is a Neuroscientist, and Lead, Optimizing Human-System Performance, at the U.S. Army Combat Capabilities Development Command, Army Research Laboratory (DEVCOM ARL).

Continue reading “Dr. Greg Lieberman, Ph.D. — Neuroscientist — Optimizing Human-System Performance, Army Research Lab” »

In June, South Korean regulators authorized the first-ever medicine, a COVID vaccine, to be made from a novel protein designed by humans. The vaccine is based on a spherical protein ‘nanoparticle’ that was created by researchers nearly a decade ago, through a labour-intensive trial-and error-process¹.

Now, thanks to gargantuan advances in artificial intelligence (AI), a team led by David Baker, a biochemist at the University of Washington (UW) in Seattle, reports in Science^2,3 that it can design such molecules in seconds instead of months.

A team of physicists and clinicians will today be honored for their development of the bladeless eye surgery technique known as LASIK, an advance partly aided by a lab mishap involving an eye and a laser.

Numerous short RNA sequences that code for microproteins and peptides have been identified, providing new opportunities for the study of diseases and the development of drugs…

At first glance, the human body looks symmetrical: two arms, two legs, two eyes, two ears, even the nose and mouth appear to be mirrored on an imaginary axis dividing the faces of most people. And finally, the brain: it is divided into two halves that are roughly the same size, and the furrows and bulges also follow a similar pattern.

But the first impression is deceptive: the different brain regions have subtle yet functionally relevant differences between the left and right sides. The two hemispheres are specialized for different functions. Spatial attention, for example, is predominantly processed in the right hemisphere in most people, while language is largely processed in the left. This way, work can be distributed more effectively to both halves and thus the range of tasks is expanded overall.

But this so-called lateralization, the tendency for brain regions to process certain functions more in the left or right hemisphere, varies from person to person. And not only in the minority whose brains are specialized mirror-inverted compared to the majority. Even people with classically arranged brains differ in how pronounced their asymmetry is.

If smoke indicates a fire, nitric oxide signals inflammation. The chemical mediator promotes inflammation, but researchers suspect it can do its job too well after anterior cruciate ligament (ACL) ruptures and related injuries and initiate early onset osteoarthritis. Typically, the degenerative disease is only diagnosed after progressive symptoms, but it potentially could be identified much earlier through nitric oxide monitoring, according to Huanyu “Larry” Cheng, James E. Henderson Jr. Memorial Associate Professor of Engineering Science and Mechanics at Penn State.

Cheng and his student, Shangbin Liu, who earned a master’s degree in engineering science and mechanics at Penn State this year, collaborated with researchers based in China to develop a flexible biosensor capable of continuous and wireless nitric oxide detection in rabbits. They published their approach in the Proceedings of the National Academy of Sciences.

“Real-time assessment of biomarkers associated with inflammation, such as nitric oxide in the joint cavity, could indicate pathological evolution at the initial development of osteoarthritis, providing essential information to optimize therapies following traumatic knee injury,” Cheng said.

A novel hormone combination has been created by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk for the potential treatment of type 2 diabetes in the future. The researchers combined the blood sugar-lowering actions of the medications tesaglitazar and GLP-1 (Glucagon-like peptide-1) to create a new and extremely effective drug.

The benefit of combining Tesaglitazar with GLP-1 is that the Tesaglitazar only penetrates the tissue with GLP-1 receptors. This increases the effects on sugar metabolism while lessening the side effects of tesaglitazar. Scientists have already successfully tested the new drug in animal studies. The study was recently published in the journal Nature Metabolism.

Tesaglitazar enhances glucose and fat metabolism in type 2 diabetic patients. It increases insulin sensitivity by acting on two receptors inside the cell nucleus. This was demonstrated in phase 3 clinical trials. However, tesaglitazar has side effects such as kidney damage.